中文摘要：

目的 分析缺血性院内卒中（in-hospital stroke,IHS）患者溶栓治疗的疗效。方法 收集近5年缺血性IHS患者临床资料,按是否接受重组组织型纤溶酶原激活剂（recombinant tissue plasminogen activato,r-tPA）溶栓治疗分为溶栓组和非溶栓组,比较两组出院时预后良好[改良Rankin量表评分（modified Rankin scale,mRS）0~2分]比例。结果 本研究共收集缺血性IHS患者121例,其中溶栓组6例,非溶栓组115例。出院时预后良好（mRS 0~2分）患者溶栓组6例（占100%）,而非溶栓组42例（占36.5%）,溶栓组预后良好比例显著高于非溶栓组（P〈0.05）。结论 缺血性IHS患者r-tPA溶栓治疗可显著改善临床预后。

英文摘要：

Objective To analyze the clinical effects of thrombolytic therapy in patients with ischemic in-hos- pital stroke （IHS）. Methods The clinical data were collected from patients with ischemic IHS in the last five years. The patients were divided into thrombolysis group and non- thrombolysis group, according to the use of recombinant tissue plasminogen activator （r-tPA） treatment. The clinical outcomes were measured by the modified Rankin scale （mRS） at discharge. Results There were a total of 121 patients in this study. There were 6 patients in thrombolysis group and 115 patients in the non-thrombolysis group, respectively. Six patients （100%） in the thrombolysis group achieved favor- able outcomes （mRS 0 ~ 2） at discharge whereas only 42 patients （36.5%） in the non- thrombolysis group achieved fa- vourable outcomes. The rate of favorable outcomes was significantly higher in the thrombolysis group than in the non-thrombolysis group （P〈 0.05）. Conclusions R-tPA thrombolytic therapy can improve the prognosis of patients with ischemic IHS.